- Home
- PVLA vs GNFT Comparison
PVLA vs GNFT Comparison
Compare PVLA & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVLA
- GNFT
- Stock Information
- Founded
- PVLA 2015
- GNFT 1999
- Country
- PVLA United States
- GNFT France
- Employees
- PVLA N/A
- GNFT N/A
- Industry
- PVLA Biotechnology: Pharmaceutical Preparations
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PVLA Health Care
- GNFT Health Care
- Exchange
- PVLA Nasdaq
- GNFT Nasdaq
- Market Cap
- PVLA 253.2M
- GNFT 214.5M
- IPO Year
- PVLA N/A
- GNFT 2019
- Fundamental
- Price
- PVLA $22.30
- GNFT $3.93
- Analyst Decision
- PVLA Strong Buy
- GNFT Strong Buy
- Analyst Count
- PVLA 7
- GNFT 1
- Target Price
- PVLA $46.29
- GNFT $13.00
- AVG Volume (30 Days)
- PVLA 81.8K
- GNFT 3.3K
- Earning Date
- PVLA 08-15-2025
- GNFT 04-24-2025
- Dividend Yield
- PVLA N/A
- GNFT N/A
- EPS Growth
- PVLA N/A
- GNFT N/A
- EPS
- PVLA N/A
- GNFT 0.03
- Revenue
- PVLA N/A
- GNFT $73,187,701.00
- Revenue This Year
- PVLA N/A
- GNFT $15.98
- Revenue Next Year
- PVLA N/A
- GNFT N/A
- P/E Ratio
- PVLA N/A
- GNFT $124.79
- Revenue Growth
- PVLA N/A
- GNFT 105.01
- 52 Week Low
- PVLA $11.17
- GNFT $2.55
- 52 Week High
- PVLA $29.27
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- PVLA N/A
- GNFT 42.09
- Support Level
- PVLA N/A
- GNFT $4.03
- Resistance Level
- PVLA N/A
- GNFT $4.61
- Average True Range (ATR)
- PVLA 0.00
- GNFT 0.12
- MACD
- PVLA 0.00
- GNFT -0.05
- Stochastic Oscillator
- PVLA 0.00
- GNFT 0.00
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.